Voyager Therapeutics (VYGR) investor relations material

Conference highlights

• Over 25 companies presented at the summit, with sessions available on demand and a full day of panels and fireside chats with key opinion leaders.

• Focus on neurotherapeutics, particularly genetically driven medicines for CNS diseases.

Pipeline and scientific updates

• Lead programs target tau, including VY1706 (vectorized siRNA gene therapy) and VY7523 (anti-tau antibody), both aiming to reduce tau pathology in Alzheimer's disease.

• VY7523 tau PET imaging data expected in the second half of 2026; goal is to outperform bepranemab in tau reduction and cognitive outcomes.

• VY1706 uses a blood-brain barrier-penetrant capsid for single-dose IV gene therapy, aiming for broad tau lowering across the brain.

• Both antibody and gene therapy approaches are being explored, with potential for combination but preference for monotherapy based on efficacy.

Industry context and rationale

• Recent positive data from Biogen's BIIB080 supports tau as a therapeutic target; tau pathology correlates strongly with clinical Alzheimer's progression.

• Tau PET imaging is prioritized as the key biomarker for tracking disease progression and therapeutic impact.

• The relationship between tau lowering and clinical benefit is still being elucidated, with more data expected from ongoing trials.